This approval was based on the findings of IMpower110 (NCT02409342), an international, randomized, open-label trial comparing the efficacy of atezolizumab to that of platinum-based chemotherapy in chemotherapy-naïve patients with stage IV NSCLC expressing PD-L1 on ≥ 1% of tumor cells (TC ≥ 1%) or tumor-infiltrating immune cells (IC ≥ 1%). Here, CD274 is linked to non-small cell lung carcinoma.